Drug intelligence / Profile preview

KapaVax

Development stage: Preclinical
Lead developer: Vaxdyn
Modality: Vaccines & Immunotherapeutics

Overview

**KapaVax** is a preclinical prophylactic trivalent bacterial vaccine developed by Vaxdyn in collaboration with Instituto de Salud Carlos III and Reig Jofre. It uses inactivated lipopolysaccharide-null, endotoxin-free whole cells of *Acinetobacter baumannii* engineered to display conserved surface antigens from *Pseudomonas aeruginosa* and *Klebsiella pneumoniae*. The candidate is intended to induce protective active immunity against infections, including antibiotic-resistant bacterial pneumonia, caused by these three priority Gram-negative pathogens. ([vaxdyn.com](https://vaxdyn.com/))

Targets

P. aeruginosa (Pseudomonas aeruginosa)

Beyond the preview

Go deeper on KapaVax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KapaVax.

Explore the full profile